Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-14
2005-06-14
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
06906036
ABSTRACT:
The invention provides inhibitors of matrix metalloproteinases that are useful for encouraging the development of healthy skin and for treating wounds. The inhibitors are peptides having sequences related to cleavage regions of the proenzyme forms of matrix metalloproteinases. The peptide inhibitors of the invention can be formulated into therapeutic compositions, lotions, creams, skin covering and wound dressings that facilitate healing and healthy skin development, discourage scarring and wrinkling and ameliorate the effects of healing.
REFERENCES:
patent: 4424552 (1984-01-01), Saint Marcoux
patent: 5270447 (1993-12-01), Liotta et al.
patent: 5280106 (1994-01-01), Liotta et al.
patent: 5372809 (1994-12-01), Liotta et al.
patent: 5585356 (1996-12-01), Liotta et al.
patent: 5698671 (1997-12-01), Stetler-Stevenson et al.
patent: 5770691 (1998-06-01), Fields et al.
patent: 5811252 (1998-09-01), Verheijen
patent: 5869277 (1999-02-01), Stetler-Stevenson et al.
patent: 6043087 (2000-03-01), Bini et al.
patent: 6127139 (2000-10-01), Te Koppele et al.
patent: 6191225 (2001-02-01), Barkac et al.
patent: 6204043 (2001-03-01), Shapiro
patent: 6274703 (2001-08-01), Goldberg
patent: 6399371 (2002-06-01), Falduto et al.
patent: 2001/0016333 (2001-08-01), Seiki et al.
patent: 2001/0031478 (2001-10-01), Bronstein et al.
patent: 2003/0096757 (2003-05-01), Quirk et al.
patent: 2003/0166567 (2003-09-01), Quirk et al.
patent: 2003/0199440 (2003-10-01), Dack et al.
patent: 0917165 (1999-05-01), None
patent: 06213888 (1994-05-01), None
patent: 06300757 (1994-10-01), None
patent: 07159402 (1995-06-01), None
patent: 08134098 (1996-05-01), None
patent: 08136548 (1996-05-01), None
patent: 08217800 (1996-08-01), None
patent: 09023889 (1997-01-01), None
patent: 09084589 (1997-03-01), None
patent: 09087299 (1997-03-01), None
patent: 09136841 (1997-05-01), None
patent: 09206099 (1997-08-01), None
patent: 10210982 (1998-08-01), None
patent: 10287700 (1998-10-01), None
patent: 10313896 (1998-12-01), None
patent: 2000270874 (2000-10-01), None
patent: 2001011093 (2001-01-01), None
patent: WO 90/10228 (1990-09-01), None
patent: WO 94/10208 (1994-05-01), None
patent: WO 96/18725 (1997-06-01), None
patent: WO 97/25437 (1997-07-01), None
patent: WO 98/04287 (1998-02-01), None
patent: WO 98/12309 (1998-03-01), None
patent: WO 98/31818 (1998-07-01), None
patent: WO 98/40475 (1998-09-01), None
patent: WO 98/42865 (1998-10-01), None
patent: WO 99/05261 (1999-02-01), None
patent: WO-99/31969 (1999-07-01), None
patent: WO 00/20860 (2000-04-01), None
patent: WO 01/10437 (2001-02-01), None
patent: WO 01/38558 (2001-05-01), None
patent: WO 01/62206 (2001-08-01), None
patent: WO 01/62261 (2001-08-01), None
patent: WO 00/63227 (2001-10-01), None
“PCT Search Report for International Application PCT US02/26319”, (Apr. 15, 2004),2 pages.
Berend, Keith R., et al., “Association between ratio of matrix metalloproteinase-1 to tissue inhibitor of metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma”,Journal of Bone&Joint Surgery—American Volume, 80(1), (1999),893-895.
Chi, Yeon Sook , et al., “Effects of the Chestnut Inner Shell Extract on the Expression of Adhesion Molecules, Fibronectin and Vitronectin, of Skin Fibroblasts in Culture”,Archives of Pharmacal Research, 25 (4), (2002),469-474.
Kerkela, E. , et al., “Human macrophage metalloelastase (MMP-12) expression is induced in chondrocytes during fetal development and malignant transformation”,Bone, 29(5), (2001),487-493.
O'Shannessy, Daniel J., “Determination of Rate and Equilibrium Binding Constants for Macromolecular Interactions Using Surface Plasmon Resonance: Use of Nonlinear Squares Analysis Methods”,Analytical Biochemistry, 212, (1993),457-468.
Sakamoto, Akio , et al., “Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma”,Journal of Cancer Research&Clinical Oncology, 125(10), (1999),541-548.
Segel, Irwin H., “Kinetics of Unireactant Enzymes”,Enzyme Kinetics, Chapter 2, (1975),18-99.
Soderstrom, M , et al., “Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas”,APMIS, 109(4), (2001),305-315.
Agren, Magnus S., “Matirx metalloproteinases (MMPs) are required for re-epitheliazation..”,arch Dermatol Res, (1999), 291:583-590.
Attie, Kenneth M., “Genetic studies in idiopathic short stature”,Current Opinion in Pediatrics, (2000), 12:400-404.
Azzam, HS , et al., “Association of MMP-2 activation potential with metastatic . . . ”,1: J Natl Cancer Inst, (1993), (21):1758-64.
Baker, EA , et al., “Proteinases, their inhibitors, and cytokine profiles in acute wound fluid.”,1: Wound Repair Regen, (2000), (5):392-8.
Becker, Joseph W., et al., “Stromelysin-1: Three-dimensional structure of the inhibited . . . ”,7-Enzymesvol. 123, (1995), 415.
Becker, Joseph W., et al., “Stromelysin-1: Three-dimensional structure of the inhibited . . . ”,Protein Science, (1995), 4:1966-1976.
Bhide, VM , et al., “Use of a fluorogenic septapeptide matrix metalloproteinase assay . . . ”,1: J PeriodontolMay 2000;71(5):690-700, (2000), 690-700.
Bickett, DM , et al., “A high throughput fluorogenic substrate for interstitial collagenase . . . ”,1: Anal Biochem, (1993), (1):58-64.
Bickett, DM , et al., “A high throughput fluorogenic substrate for stromelysin (MMP-2).”,1: Ann N Y Acad Sci, (1994), 732:351-5.
Blaschke, Rudiger J., et al., “SHOX: Growth, Leri-Weill and Turner Syndromes”,TEMvol. 11, (2000), 227-230.
Bremer, C , et al., “In Vivo molecular toarget assessment or matrix metaloproteinase . . . ”,1: Nat Med, (2001), (6):743-8.
Brown, Peter D., “Cellular activation of the 72 kDa type IV pro collagenase/TIMP-2 complex”,13-Mammalion Biochem, vol. 119., (1993), 573.
Brown, PD , et al., “Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 . . . ”,1: Kidney Int, (1993), (1):163-70.
Brown, Rebeccah L., et al. et al., “PDGF and TGF-a Act Synergistically to Improve Wound Healing . . . ”,Journal of Surgical Research56, (1994), 562-570.
Browner, Michelle F., et al., “Matrilysin-Inhibitor Complexes: Common Themes among Metalloproteases”,Biochemistry, (1995), 34, 6602-6610.
Cabrele, Chiara , et al., “Y-receptor affinity modulation by the design of pancreatic..”,Peptides 22, (2001), 365-378.
Calabrese, Edward J., “Cell Migration / Chemotaxis: Biphasic Dose Responses”,Critical Reviews in Toxicology, 31 (4&5), (2001), 615-624.
Calvin, Melissa , “Cutaneous Wound Repair”,Wounds: A Compendium of Clinical Research and Practicevol. 10 No. 1, (1998), 12-32.
Chen, LC , et al., “Disruption of the cysteine-75 and zinc ion coordination is not sufficient . . . ”,1: Biochemistry, (1993),(39):10289-95.
Chin, Jason W., et al., “Concerted Evolution of Structureand Function in a Miniature Protein . . . ”,J. Am. Chem. Soc., (2001), 2929-2930.
Chin, Jason W., et al., “Methodology for Optimizing Functional Miniature Proteins Based on Avian . . . ”,Bioorganic, (2001),(2001) 1501-1505.
Clark, Richard A., “Wound Repair”,The Molecular and Cellular Bilogy of Wound Repair—2nd ed., (1996), 3-50.
Colandrea, Teresa D., et al., “Epidermal Expression of Coilagenase Delays Wound-Healing . . . ”,The Society of Investigative Dermatology, (1998), 1029-1033.
Duivenoorden, Wilhelmina C., et al., “Use of Tetracycline as an Inhiitor of Matrix Metalloproteinase . . . ”,Invasion Metastasis, (1997), 312-322.
Duncan, ME , et al., “Human matrix metalloproteinase-9: activation by limited trypsin”,1:Eur J B
Malik Sohail
Quirk Stephen
Audet Maury
Schwegman Lundberg Woessner & Kluth PA
Tate Christopher R.
LandOfFree
Anti-aging and wound healing compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-aging and wound healing compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-aging and wound healing compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3521089